AngioDynamics Inc. (ANGO) is a leading global medical device company committed to providing innovative, minimally invasive solutions for physicians and patients worldwide. The company was founded in 1988, with its headquarters in New York, United States. In the three decades since its founding, AngioDynamics has established a robust reputation for developing innovative and effective medical technologies that enhance patient outcomes and provide cost-efficient solutions to medical professionals.
AngioDynamics Inc. operates through three primary business segments: Vascular Interventions & Therapies (VIT), Oncology, and Vascular Access (VA). Each division focuses on specific areas of care, ensuring the company stays ahead of the curve in its innovative specialties. The company’s VIT offering includes groundbreaking devices like AngioVac, a powerful system for removing harmful material like clots from blood vessels. In the oncology segment, the company is a pioneer in the development of therapies such as NanoKnife, which uses electric currents to destroy hard-to-reach or inoperable tumors.
The company's reputation in the medical industry is firmly rooted in its steadfast commitment to serving patients. Their products are designed to ensure patient safety, improve outcomes, and reduce the total cost of care. The patient-first approach has been central to their manifold achievements in improving both patient outcomes and the efficacy of the physicians and medical staff who use their products.
Moreover, AngioDynamics is recognized for its deep commitment to R&D, as evidenced by a robust pipeline of products. It is dedicated to constant product innovation, aiming to improve the quality of patient care and offer cost-saving solutions for healthcare providers. Beyond the medical benefits, their products are intuitively designed with clinicians in mind, ensuring that they are easy to use, saving time, and reducing stress for healthcare providers.
The company is listed on the NASDAQ Stock Exchange under the symbol ANGO. It stands firmly focused on innovation, patient outcomes, and physician efficiency, with ethics and integrity vitally integral to its operation. Its dedication to creating state-of-the-art medical devices that enhance patient care while maximizing efficiency for medical professionals has positioned AngioDynamics Inc. as a leader in the global medical device industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
A Delaware woman has filed a product liability lawsuit against AngioDynamics, claiming her Xcela port catheter was defectively designed, migrated, and caused infection. The lawsuit alleges that AngioDynamics failed to warn about the risks of migration, fractures, and infections associated with their port catheters. This case joins hundreds of similar AngioDynamics port catheter lawsuits consolidated in federal court, alleging defective designs and inadequate warnings.
Western Standard LLC has acquired 387,188 shares of AngioDynamics, Inc. (NASDAQ:ANGO) for approximately $5.04 million, making it their 17th largest position. AngioDynamics recently beat quarterly earnings expectations, reporting a loss of $0.07 per share on $86.61 million in revenue, exceeding estimates despite remaining unprofitable. Analyst sentiment is mixed, with a consensus "Hold" rating and a price target of $19.50.
AngioDynamics (NASDAQ:ANGO) has reached a new 52-week high of $16.25, with mixed analyst ratings including "buy" and "strong sell." Despite beating quarterly earnings and revenue estimates, the company remains unprofitable, and an insider recently sold shares. The consensus rating for ANGO is "Hold" with a $19.50 price target.
This article from Stock Traders Daily provides an AI-driven analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and significant upside potential due to a lack of resistance levels. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The report emphasizes real-time signals, risk management parameters, and advanced AI models for optimizing trading decisions.
AngioDynamics (ANGO) shares have increased 33.5% in the last three months, outperforming the market and medical sector, driven by growing interest in its Med Tech platforms. While Med Tech revenue growth and products like NanoKnife and Auryon show promise, valuation concerns, tariffs, and a negative earnings outlook temper future upside. The stock currently holds a Zacks Rank #4 (Sell), suggesting caution due to its valuation and execution risks despite operational improvements.
AngioDynamics' Senior Vice President of Regulatory Affairs, Warren Nighan, recently sold US$344k worth of stock, representing 27% of his holding. While other insiders have purchased shares over the past year, this significant sale and a general trend of insider selling raise caution. Despite insiders owning 10% of the company, the net insider activity suggests a lack of strong confidence.